--- title: "The research report \"Big Banks\" raised the target price of Tigermed to 64.6 yuan, with last year's revenue and new orders exceeding expectations" description: "HSBC's research report indicates that Tigermed's revenue and recurring net profit forecasts for last year exceeded expectations, with new order amounts ranging from RMB 9.5 billion to 10.5 billion, re" type: "news" locale: "en" url: "https://longbridge.com/en/news/275395644.md" published_at: "2026-02-10T03:02:56.000Z" --- # The research report "Big Banks" raised the target price of Tigermed to 64.6 yuan, with last year's revenue and new orders exceeding expectations > HSBC's research report indicates that Tigermed's revenue and recurring net profit forecasts for last year exceeded expectations, with new order amounts ranging from RMB 9.5 billion to 10.5 billion, representing a year-on-year growth of 18.7%. The bank has raised its revenue forecast for 2026 to 2027 by 7%, but lowered its recurring net profit forecast by 1% to 3%. It maintains a "Buy" rating and raises the target price from HKD 59 to HKD 64.6, expecting the company's business recovery trend to continue HSBC's research report indicates that Tigermed (03347.HK) announced its revenue and recurring net profit forecasts for last year; based on the midpoint, it represents a year-on-year increase of 8.6% and a year-on-year decrease of 52%, respectively. The new order amount is estimated to be between 9.5 billion and 10.5 billion RMB, which translates to a year-on-year growth of 18.7% based on the midpoint. During the period, revenue and new orders exceeded the bank's expectations by 7% and 3%, respectively, while recurring net profit was 10% lower than expected. The bank has raised its revenue forecast for 2026 to 2027 by 7%, but lowered the recurring net profit forecast for the same period by 1% to 3%; it maintains a "Buy" rating, raising the target price for Tigermed's H shares from HKD 59 to HKD 64.6, and the target price for Tigermed's A shares (300347.SZ) from RMB 78.5 to RMB 86, expecting the company's business recovery trend to continue, with robust new orders and average service prices supporting margin improvement ### Related Stocks - [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md) - [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md) - [03347.HK - TIGERMED](https://longbridge.com/en/quote/03347.HK.md) - [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md) - [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md) - [513290.CN - China Universal NASDAQ Biotechnology Technology ETF(QDII)](https://longbridge.com/en/quote/513290.CN.md) - [300347.CN - Tigermed](https://longbridge.com/en/quote/300347.CN.md) - [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) | | 埃隆·馬斯克的 Neuralink 在中國激發了腦機接口技術的競賽 | Neuralink，由埃隆·馬斯克創立，正在推動中國腦機接口（BCI）發展的熱潮，像 NeuroXess 這樣的初創公司迅速進入人體試驗階段。NeuroXess 於 2021 年成立，已經在患者身上測試植入物。中國政府已將 BCI 列為戰略 | [Link](https://longbridge.com/en/news/276460367.md) | | 現貨白銀上漲 3%，達到每盎司 75.68 美元 | 現貨白銀上漲 3%，至每盎司 75.68 美元 | [Link](https://longbridge.com/en/news/276197641.md) | | EKF Diagnostics Holdings 宣佈了一項股票回購計劃，最多回購 500 萬股 | EKF Diagnostics Holdings PLC：EKF DIAGNOSTICS HOLDINGS PLC - 宣佈最多回購 500 萬股股票的股份回購計劃 | [Link](https://longbridge.com/en/news/276310546.md) | | 基石藥業-B 的肺癌藥物 Sugemalimab 獲得英國第二次批准 | 藥明康德（CStone Pharmaceuticals）已獲得英國批准，將其肺癌藥物 sugemalimab 作為單藥治療用於不可切除的 III 期非小細胞肺癌成人患者。這標誌着該藥物在英國的第二個適應症，得益於 III 期 GEMSTON | [Link](https://longbridge.com/en/news/276549711.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.